|
US4708871A
(en)
|
1983-03-08 |
1987-11-24 |
Commonwealth Serum Laboratories Commission |
Antigenically active amino acid sequences
|
|
IL86278A
(en)
*
|
1988-05-04 |
2003-06-24 |
Yeda Res & Dev |
Endowing cells with antibody specificity using chimeric t cell receptor
|
|
US5906936A
(en)
*
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
TWI224995B
(en)
|
1998-03-19 |
2004-12-11 |
Ciba Sc Holding Ag |
Stabilization of wood substrates
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
PT1390389E
(pt)
|
2001-04-26 |
2009-04-03 |
Biogen Idec Inc |
Anticorpos que bloqueiam o cripto e as utilizações dos mesmos
|
|
AU2002321581C1
(en)
|
2001-08-31 |
2008-09-18 |
Adaptimmune Limited |
Soluble T cell receptor
|
|
IL159422A0
(en)
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
|
CA2467242A1
(en)
|
2001-11-20 |
2003-05-30 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
|
AU2003216341A1
(en)
|
2002-02-20 |
2003-09-09 |
Dyax Corporation |
Mhc-peptide complex binding ligands
|
|
AU2003271904B2
(en)
*
|
2002-10-09 |
2009-03-05 |
Adaptimmune Limited |
Single chain recombinant T cell receptors
|
|
GB0304068D0
(en)
*
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
|
CU23403A1
(es)
|
2003-04-23 |
2009-08-04 |
Centro Inmunologia Molecular |
Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
|
NZ550815A
(en)
*
|
2004-05-19 |
2009-04-30 |
Immunocore Ltd |
Method of improving T cell receptors
|
|
DK1765860T3
(da)
|
2004-05-19 |
2009-03-09 |
Immunocore Ltd |
Ny-ESO-T.cellereceptor med höj affinitet
|
|
AU2005250408B2
(en)
*
|
2004-05-27 |
2010-09-23 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
EP1612224B1
(en)
|
2004-06-29 |
2012-03-07 |
B.R.A.H.M.S GmbH |
Novel monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine
|
|
WO2006039418A2
(en)
|
2004-09-30 |
2006-04-13 |
Medarex, Inc. |
Human monoclonal antibodies to fc gamma receptor ii (cd32)
|
|
AU2005291039A1
(en)
*
|
2004-10-01 |
2006-04-13 |
Avidex Ltd. |
T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
|
|
AU2005322410B2
(en)
|
2004-11-30 |
2011-11-10 |
Amgen Fremont Inc. |
Antibodies directed to GPNMB and uses thereof
|
|
ES2408704T3
(es)
|
2005-01-05 |
2013-06-21 |
Biogen Idec Ma Inc. |
Moléculas de unión a Cripto
|
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
WO2007002223A2
(en)
|
2005-06-20 |
2007-01-04 |
Medarex, Inc. |
Cd19 antibodies and their uses
|
|
US8383118B2
(en)
|
2005-12-08 |
2013-02-26 |
Medarex, Inc. |
Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
|
|
EA017812B1
(ru)
|
2005-12-08 |
2013-03-29 |
Медарекс, Инк. |
Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение
|
|
AU2006332155B2
(en)
|
2005-12-30 |
2013-01-10 |
Cancer Research Technology Limited |
Anti-CD19 antibodies with reduced immunogenicity
|
|
US20080131428A1
(en)
|
2006-02-24 |
2008-06-05 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
ES2567402T3
(es)
|
2006-05-30 |
2016-04-22 |
Genentech, Inc. |
Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
|
|
KR101456728B1
(ko)
|
2006-09-08 |
2014-10-31 |
메디뮨 엘엘씨 |
인간화 항-ｃｄ19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
|
|
EP2620429A1
(en)
|
2007-02-22 |
2013-07-31 |
Colby Pharmaceutical Company |
Hydroxylamine compounds and methods of their use
|
|
EP2014302A1
(en)
|
2007-07-12 |
2009-01-14 |
Institut Curie |
An antibody specific for the Tn antigen for the treatment of cancer
|
|
EP2186825A1
(en)
*
|
2008-11-13 |
2010-05-19 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Human-derived T cell receptors
|
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
|
WO2010093480A2
(en)
|
2009-02-16 |
2010-08-19 |
Biolex Therapeutics, Inc. |
Humanized anti-cd20 antibodies and methods of use
|
|
EP2398829A2
(en)
|
2009-02-23 |
2011-12-28 |
Glenmark Pharmaceuticals S.A. |
Humanized antibodies that bind to cd19 and their uses
|
|
CA2755686A1
(en)
|
2009-03-16 |
2010-09-23 |
Daniel A. Vallera |
Methods and compositions for bi-specific targeting of cd19/cd22
|
|
DK2421898T3
(en)
|
2009-04-20 |
2016-05-30 |
Oxford Biotherapeutics Ltd |
Cadherin-17 SPECIFIC ANTIBODIES
|
|
WO2011009090A1
(en)
|
2009-07-16 |
2011-01-20 |
Xoma Technology Ltd. |
Antibodies to high molecular weight melanoma associated antigen
|
|
MY173390A
(en)
|
2009-10-23 |
2020-01-22 |
Takeda Pharmaceuticals Co |
Anti-gcc antibody molecules and related compositions and methods
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
WO2011060076A1
(en)
|
2009-11-10 |
2011-05-19 |
Amgen Inc. |
Anti-c-mpl antibodies
|
|
PT2552959T
(pt)
|
2010-03-26 |
2017-04-21 |
Memorial Sloan Kettering Cancer Center |
Anticorpos para muc16 e métodos de utilização dos mesmos
|
|
JP2013532126A
(ja)
|
2010-05-11 |
2013-08-15 |
フレッド ハッチンソン キャンサー リサーチ センター |
クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
|
|
CN102906118B
(zh)
|
2010-05-20 |
2017-07-28 |
埃博灵克斯股份有限公司 |
与her3相关的生物材料
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
US9163258B2
(en)
|
2010-07-23 |
2015-10-20 |
Fred Hutchinson Cancer Research Center |
Method for the treatment of obesity
|
|
AR082641A1
(es)
|
2010-09-07 |
2012-12-19 |
Imclone Llc |
Composiciones de anticuerpo anti-vegfr-3
|
|
EP2621953B1
(en)
|
2010-09-30 |
2017-04-05 |
Ablynx N.V. |
Biological materials related to c-met
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
CN108424462A
(zh)
|
2010-10-27 |
2018-08-21 |
贝勒医学院 |
使t细胞重定向针对cd70阳性恶性肿瘤的嵌合cd27受体
|
|
KR20140033029A
(ko)
|
2011-04-01 |
2014-03-17 |
메모리얼 슬로안-케터링 캔서 센터 |
에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
|
|
CA2833820C
(en)
|
2011-05-27 |
2019-10-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
AU2012267710A1
(en)
|
2011-06-08 |
2014-01-23 |
The Regents Of The University Of California |
Anti-CD22 antigen binding molecules to treat lung cancer and prostate cancer
|
|
WO2013019730A1
(en)
|
2011-07-29 |
2013-02-07 |
The Washington University |
Antibodies to tip-1 and grp78
|
|
PL2744515T3
(pl)
|
2011-08-16 |
2022-05-30 |
Morphosys Ag |
Terapia skojarzona przeciwciałem anty-cd19 i iperytem azotowym
|
|
CN107058101B
(zh)
|
2011-10-17 |
2021-06-01 |
麻省理工学院 |
细胞内传递
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
|
PE20190658A1
(es)
|
2012-02-24 |
2019-05-08 |
Abbvie Stemcentrx Llc |
Moduladores y metodos de empleo novedosos
|
|
WO2013130565A1
(en)
|
2012-02-29 |
2013-09-06 |
The Brigham And Women's Hosptial, Inc. |
Neutralizing antibody for epstein barr virus associated disease
|
|
CN104640560A
(zh)
|
2012-03-12 |
2015-05-20 |
米迪缪尼有限公司 |
用抗-cd19抗体治疗多发性硬化症
|
|
US9163090B2
(en)
|
2012-05-07 |
2015-10-20 |
Cellerant Therapeutics, Inc. |
Antibodies specific for CLL-1
|
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
KR102437522B1
(ko)
|
2012-05-25 |
2022-08-26 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
|
CN104955845B
(zh)
|
2012-09-27 |
2018-11-16 |
美国政府(由卫生和人类服务部的部长所代表) |
间皮素抗体和引起有效的抗肿瘤活性的方法
|
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
US9803021B2
(en)
|
2012-12-07 |
2017-10-31 |
The Regents Of The University Of California |
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
|
ES2871816T3
(es)
|
2012-12-27 |
2021-11-02 |
Sanofi Sa |
Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
PT2961831T
(pt)
|
2013-02-26 |
2020-10-12 |
Memorial Sloan Kettering Cancer Center |
Composições e métodos para imunoterapêutica
|
|
EP2964253A1
(en)
|
2013-03-05 |
2016-01-13 |
Baylor College Of Medicine |
Heparanase expression in human t lymphocytes
|
|
CN105339498A
(zh)
|
2013-03-07 |
2016-02-17 |
贝勒医学院 |
癌症中靶向cd138
|
|
EP2970312B1
(en)
|
2013-03-11 |
2017-11-15 |
The Regents of The University of Michigan |
Bet bromodomain inhibitors and therapeutic methods using the same
|
|
CA2906551A1
(en)
|
2013-03-15 |
2014-09-25 |
Wake Forest University Health Sciences |
Antibodies against human and canine il-13ra2
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
|
CN104140974B
(zh)
|
2013-05-08 |
2017-09-29 |
科济生物医药（上海）有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
|
EP3783098A1
(en)
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
AU2014268364A1
(en)
|
2013-05-24 |
2015-12-10 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
US10000746B2
(en)
|
2013-05-31 |
2018-06-19 |
Cellectis |
LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof
|
|
GB201313377D0
(en)
|
2013-07-26 |
2013-09-11 |
Adaptimmune Ltd |
T cell receptors
|
|
CA2954168C
(en)
|
2013-08-02 |
2023-09-19 |
The Regents Of The University Of California |
Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
|
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
|
GB201317929D0
(en)
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
EP3057991B8
(en)
|
2013-10-15 |
2019-09-04 |
The Scripps Research Institute |
Chimeric antigen receptor t cell switches and uses thereof
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
US10246505B2
(en)
|
2013-11-25 |
2019-04-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control HIV infection
|
|
US20160376375A1
(en)
|
2013-11-27 |
2016-12-29 |
Baylor College Of Medicine |
CSGP4 - Specific Chimeric Antigen Receptor for Cancer
|
|
EA201691214A1
(ru)
|
2013-12-13 |
2016-12-30 |
Дженентек, Инк. |
Антитела к cd33 и иммуноконъюгаты
|
|
US10214584B2
(en)
|
2014-01-15 |
2019-02-26 |
Order-Made Medical Research Inc. |
Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
|
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
|
US20170145108A1
(en)
|
2014-02-05 |
2017-05-25 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
CN112094347A
(zh)
|
2014-03-05 |
2020-12-18 |
奥托路斯有限公司 |
具有针对T细胞受体beta恒定区的抗原结合域的嵌合抗原受体(CAR)
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
SI3126381T2
(sl)
|
2014-04-01 |
2022-05-31 |
Biontech Cell&Gene Therapies Gmbh |
Claudin-6-specifični imunoreceptorji in t-celični epitopi
|
|
GB201406767D0
(en)
|
2014-04-15 |
2014-05-28 |
Cancer Rec Tech Ltd |
Humanized anti-Tn-MUC1 antibodies anf their conjugates
|
|
LT3134432T
(lt)
|
2014-04-25 |
2020-04-10 |
Bluebird Bio, Inc. |
Mnd promotorius chimerinių antigenų receptoriams
|
|
DK3166968T3
(da)
|
2014-05-02 |
2021-12-06 |
Univ Pennsylvania |
Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
|
|
EP2944652A1
(en)
*
|
2014-05-13 |
2015-11-18 |
Technische Universität München |
Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
|
|
IL290655B2
(en)
*
|
2014-05-29 |
2024-05-01 |
Us Health |
Anti-human papillomavirus 16 E7 T-cell chelates
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
CN107074970B
(zh)
*
|
2014-08-04 |
2021-07-30 |
弗雷德哈钦森癌症研究中心 |
特异性针对wt-1的t细胞免疫疗法
|
|
KR20170040249A
(ko)
|
2014-08-12 |
2017-04-12 |
노파르티스 아게 |
항-cdh6 항체 약물 접합체
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
CN106661129B
(zh)
|
2014-08-19 |
2021-02-05 |
美天施生物科技有限两合公司 |
对ssea4抗原具有特异性的嵌合抗原受体
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
US10093746B2
(en)
|
2014-09-04 |
2018-10-09 |
The Trustees Of The University Of Pennsylvania |
Glypican-3 antibody and uses thereof
|
|
JO3568B1
(ar)
|
2014-09-05 |
2020-07-05 |
Janssen Pharmaceutica Nv |
عوامل ربط cd123 واستخداماتها
|
|
US20180133252A9
(en)
|
2014-09-09 |
2018-05-17 |
Unum Therapeutics Inc. |
Chimeric receptors and uses thereof in immune therapy
|
|
KR20170066421A
(ko)
|
2014-09-12 |
2017-06-14 |
제넨테크, 인크. |
항-cll-1 항체 및 면역접합체
|
|
CA2959428A1
(en)
|
2014-09-19 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors
|
|
JP2017529851A
(ja)
|
2014-09-26 |
2017-10-12 |
ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ |
養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター
|
|
EP3212668B1
(en)
|
2014-10-31 |
2020-10-14 |
AbbVie Biotherapeutics Inc. |
Anti-cs1 antibodies and antibody drug conjugates
|
|
CA2965521A1
(en)
|
2014-10-31 |
2016-05-06 |
Baylor College Of Medicine |
Survivin specific t-cell receptor targeting tumor but not t cells
|
|
RS60739B1
(sr)
|
2014-11-17 |
2020-09-30 |
Regeneron Pharma |
Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
|
|
EP3227324A4
(en)
|
2014-12-05 |
2018-08-29 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting g-protein coupled receptor and methods of use
|
|
SI3227339T1
(sl)
|
2014-12-05 |
2022-02-28 |
Memorial Sloan-Kettering Cancer Center |
Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
|
|
KR20240135036A
(ko)
|
2014-12-05 |
2024-09-10 |
메모리얼 슬로안 케터링 캔서 센터 |
B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
|
|
EA036379B1
(ru)
|
2014-12-12 |
2020-11-02 |
Блубёрд Био, Инк. |
Химерные антигенные рецепторы к bcma
|
|
KR102376244B1
(ko)
|
2014-12-24 |
2022-03-21 |
오토러스 리미티드 |
세포
|
|
CR20170383A
(es)
|
2015-01-23 |
2017-11-22 |
Sanofi Sa |
Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
|
|
ES2869972T3
(es)
|
2015-01-26 |
2021-10-26 |
Cellectis |
Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
|
|
WO2016126488A1
(en)
|
2015-02-02 |
2016-08-11 |
Sea Lane Biotechnologies, Llc |
Anti-surrogate light chain antibodies
|
|
WO2016154047A2
(en)
|
2015-03-20 |
2016-09-29 |
Memorial Sloan-Kettering Cancer Center |
Monoclonal antigen-binding proteins to intracellular oncogene products
|
|
AU2016243124A1
(en)
|
2015-03-27 |
2017-11-02 |
University Of Southern California |
CAR T-cell therapy directed to LHR for the treatment of solid tumors
|
|
KR20260048600A
(ko)
|
2015-03-27 |
2026-04-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
변형된 t 세포 및 이의 제조 및 사용 방법
|
|
EP3283520B1
(en)
|
2015-04-13 |
2020-05-06 |
Pfizer Inc |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
WO2016176639A1
(en)
|
2015-04-30 |
2016-11-03 |
University Of Southern California |
Secretory tnt car cell immunotherapy
|
|
EP3292222B1
(en)
|
2015-05-06 |
2025-09-03 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen binding fibronectin type iii domains
|
|
PT3294768T
(pt)
|
2015-05-13 |
2019-11-05 |
Ablynx Nv |
Polipétidos de recrutamento de células t com base na reatividade do tcr alfa/beta
|
|
CN107995913B
(zh)
*
|
2015-05-18 |
2022-02-11 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
|
KR20180023949A
(ko)
|
2015-06-09 |
2018-03-07 |
메모리얼 슬로안-케터링 캔서 센터 |
인간 hla에 의해 제시된 ebv 잠복성 막 단백질 2a 펩티드에 특이적인 t 세포 수용체-유사 항체 작용제
|
|
US9422547B1
(en)
*
|
2015-06-09 |
2016-08-23 |
Gigagen, Inc. |
Recombinant fusion proteins and libraries from immune cell repertoires
|
|
US11649435B2
(en)
|
2015-08-28 |
2023-05-16 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
US20180258149A1
(en)
|
2015-09-17 |
2018-09-13 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
CA3001833A1
(en)
|
2015-10-13 |
2017-04-20 |
City Of Hope |
Chimeric antigen receptors containing a chlorotoxin domain
|
|
EP3842450A1
(en)
*
|
2015-10-23 |
2021-06-30 |
Eureka Therapeutics, Inc. |
Antibody/t-cell receptor chimeric constructs and uses thereof
|
|
AU2016350705A1
(en)
|
2015-11-02 |
2018-05-17 |
Janssen Pharmaceutica Nv |
Anti-IL1RAP antibodies, bispecific antigen binding molecules that bind IL1RAP and CD3, and uses thereof
|
|
CA3018253A1
(en)
|
2016-03-31 |
2017-10-05 |
University Of Southern California |
A highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
PT3436079T
(pt)
|
2016-04-01 |
2021-10-06 |
Kite Pharma Inc |
Recetores de antigénios quiméricos e de células t e métodos de uso
|
|
CN109414455B
(zh)
|
2016-04-01 |
2023-01-20 |
凯德药业股份有限公司 |
Bcma结合分子及其使用方法
|
|
US12060394B2
(en)
|
2016-04-28 |
2024-08-13 |
The Trustees Of Dartmouth College |
Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
|
|
WO2017192536A1
(en)
*
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
|
US11382931B2
(en)
|
2016-07-14 |
2022-07-12 |
University Of Southern California |
Methods and composition for producing and using immune cells and stem cells for cell-based therapies
|
|
JP2019524721A
(ja)
|
2016-07-15 |
2019-09-05 |
ポセイダ セラピューティクス， インコーポレイテッド |
キメラ抗原受容体および使用方法
|
|
EP4596707A3
(en)
|
2016-09-19 |
2025-10-08 |
University of Southern California |
Non-radioactive cytotoxicity assays
|
|
GB2595980B
(en)
|
2019-01-04 |
2023-06-14 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|